SCHEMBL6173541

SCHEMBL6173541

NC(=O)N1COc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.51
HSD17B3 P37058 2/20 0.49
POLB P06746 2/20 0.44
PDK1 Q15118 1/20 0.42
THRB P10828 1/20 0.40
LMNA P02545 3/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
SCN4A P35499 1/20 0.39
SCN5A Q14524 1/20 0.39
SCN9A Q15858 1/20 0.39
SIRT1 Q96EB6 2/20 0.39
MAPT P10636 2/20 0.39
SIRT3 Q9NTG7 1/20 0.39
KMT2A Q03164 2/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
P2RX4 Q99571 1/20 0.38
RXFP1 Q9HBX9 2/20 0.37
DRD2 P14416 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4444354 0.83 NOTUM (0.53) NOTUMHSD17B3POLBPDK1THRB
SCHEMBL1548726 0.82 NOTUM (0.71) NOTUMPOLBPDK1THRBLMNA
Hydrochloric Acid SCHEMBL23320556 0.81 NOTUM (0.51) NOTUMHSD17B3POLBPDK1THRB
Hydrochloric Acid SCHEMBL27851171 0.81 NOTUM (0.69) NOTUMPOLBPDK1THRBLMNA
SCHEMBL19859267 0.80 NOTUM (0.58) NOTUMHSD17B3POLBPDK1THRB
SCHEMBL18964807 0.75 NOTUM (0.45) NOTUMHSD17B3POLBTHRBLMNA
SCHEMBL5564148 0.74 KMT2A (0.48) NOTUMPOLBTSHRSIRT1MAPT
SCHEMBL2543890 0.74 NOTUM (0.44) NOTUMHSD17B3POLBPDK1THRB
SCHEMBL18343579 0.72 THRB (0.47) NOTUMHSD17B3THRBLMNAMAPT
Acetic Acid SCHEMBL27604418 0.71 NOTUM (0.49) NOTUMHSD17B3POLBLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3472149-B1 HETEROCYCLIC PROLINAMIDE DERIVATIVES Orion Ophthalmology LLC (US) 2023-08-30 EP claimed
CN-1726033-A Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds PHARMACIA & UPJOHN CO LLC (US) 2006-01-25 CN claimed
EP-1534693-A2 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2005-06-01 EP claimed
EP-1453789-A2 N,N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES Elan Pharmaceuticals, Inc. (US) 2004-09-08 EP claimed
WO-2004022523-A2 1, 3-DIAMINO-2-HYDROXYPROPANE PRODRUG DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2004-03-18 WO claimed
WO-2003040096-A2 N, N'-SUBSTITUTED-1,3-DIAMINO-2-HYDROXYPROPANE DERIVATIVES ELAN PHARMACEUTICALS, INC. (US) 2003-05-15 WO claimed
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2025-01-02 US disclosed
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-09-19 US disclosed
US-20220106281-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-04-07 US disclosed
US-10913727-B2 Modulators of the integrated stress pathway ABBVIE INC. (US) 2021-02-09 US disclosed
US-20200345727-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2020-11-05 US disclosed
EP-3710428-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2020-09-23 EP disclosed
WO-2020132582-A1 STING AGONISTS AND USES THEREOF NIMBUS TITAN, INC. (US) 2020-06-25 WO disclosed
CN-108349947-A Tetrahydrochysene indazole and its medical usage S·莱恩 2018-07-31 CN disclosed
EP-3313386-A1 METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS Lysosomal Therapeutics Inc. (US) 2018-05-02 EP disclosed
WO-2017077280-A1 TETRAHYDROINDAZOLES AND MEDICAL USES THEREOF LAIN SONIA (SE) 2017-05-11 WO disclosed
WO-2016210116-A1 METHODS AND COMPOSITIONS FOR TREATING LYSOSOMAL STORAGE DISORDERS LYSOSOMAL THERAPEUTICS INC. (US) 2016-12-29 WO disclosed
WO-2015173168-A1 BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2015-11-19 WO disclosed
CN-104520279-A Novel 1,3-benzoxazol-2(3H)-ones and their use as medicaments and cosmetics WOLFF AUGUST GMBH & CO KG ARZNEIMITTEL DR 2015-04-15 CN disclosed
CN-1726033-A Treatment of diseases with combinations of alpha 7 nicotinic acetylcholine receptor agonists and other compounds PHARMACIA & UPJOHN CO LLC (US) 2006-01-25 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250002487-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF CGAS, TDP1, CYP11B2 NOTUM 3860/4885HSD17B3 133/4885POLB 727/4885
US-10913727-B2 Modulators of the integrated stress pathway ATF4, ATF1, DDIT3 NOTUM 4143/4885HSD17B3 1207/4885POLB 1764/4885
US-20240307382-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 NOTUM 4143/4885HSD17B3 1207/4885POLB 1764/4885
US-20220106281-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 NOTUM 4143/4885HSD17B3 1207/4885POLB 1764/4885
US-20200345727-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 NOTUM 4143/4885HSD17B3 1207/4885POLB 1764/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.